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Abstract: Physical frailty and sarcopenia (PF&S) recapitulates all the hallmarks of aging and has
become a focus in geroscience. Factors spanning muscle-specific processes (e.g., mitochondrial
dysfunction in skeletal myocytes) to systemic changes (e.g., inflammation and amino acid
dysmetabolism) have been pinpointed as possible contributors to PF&S pathophysiology. However,
the search for PF&S biomarkers allowing the early identification and tracking of the condition
over time is ongoing. This is mainly due to the phenotypic heterogeneity of PF&S, its unclear
pathophysiology, and the frequent superimposition of other age-related conditions. Hence, presently,
the identification of PF&S relies upon clinical, functional, and imaging parameters. The adoption
of multi-marker approaches (combined with multivariate modeling) has shown great potential for
addressing the complexity of PF&S pathophysiology and identifying candidate biological markers.
Well-designed longitudinal studies are necessary for the incorporation of reliable biomarkers into
clinical practice and for unveiling novel targets that are amenable to interventions.
Keywords: cytokines; extracellular vesicles; exosomes; geroscience; gut dysbiosis; inflammation;
metabolomics; mitochondrial dysfunction; physical performance; skeletal muscle
1. Introduction
Sarcopenia is the progressive decline in muscle mass and strength that occurs during aging [1].
This condition is a hot topic in geriatric research and a public health priority [2], as it exposes older
adults to increased risk of negative health-related events (such as disability, loss of independence,
institutionalization, and death) [1]. However, its phenotypic heterogeneity, the unclear pathophysiology,
and the frequent superimposition of other age-related conditions hamper the study of sarcopenia as a
single phenomenon [3]. As a result, an univocal operational definition of sarcopenia is still missing,
as are specific biomarkers that could be used, either in clinics or in research [4]. At the clinical level,
sarcopenia overlaps with frailty and the age-related decline in physiologic reserve and homeostatic
capacity, which predisposes older adults to a wide range of negative health-related events—including
falls, morbidity, disability, hospitalization, institutionalization, and mortality [5]. In this scenario,
the recognition of physical frailty and sarcopenia (PF&S) as a new entity, and its operationalization in
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the Sarcopenia and Physical fRailty IN older people: multi-componenT Treatment strategies (SPRINTT)
project, have set a remarkable precedent for its clinical and regulatory recognition [6].
The decline in physical function is, indeed, the most evident change that occurs during sarcopenia,
and a cardinal criterion for the identification of PF&S [7–10]. Physical function refers to a construct
encompassing simple single-joint (e.g., handgrip strength) and multi-joint complex movements
(e.g., walking speed), and may be assessed through a large array of tests [11,12]. Changes in physical
performance occur slowly across years [11,13–15] and show great heterogeneity among people from
different socioeconomic backgrounds [14]. This implies that age- and country-specific cut-off values
might be needed in order to identify physical dysfunction [16]. At the same time, when considering
physical dysfunction as the ultimate outcome of muscle failure [17], numerous cellular and molecular
changes may occur alongside this phenomenon.
When exploring the pathways and processes involved in PF&S pathophysiology, several factors,
from muscle-specific mitochondrial dysfunction to systemic changes (e.g., inflammation and amino
acid dysmetabolism), have been pinpointed [9,10,18]. It is still unclear whether these processes
share common roots and how cell-based alterations spread and are detected at the systemic level,
contributing to the disabling cascade that characterizes PF&S. Low-grade inflammation and amino
acid dysmetabolism have recently been associated with a specific pattern of small extracellular vesicles
(sEVs) of mitochondrial origin, namely mitochondrial-derived vesicles (MDVs), which are proposed to
function as shuttles that allow crosstalk between biological systems [7]. However, little is known about
their complex regulatory network.
A conceptual framework has recently been agreed upon for the selection of blood-borne biomarkers
to verify the existence of shared “hallmarks of aging” that can be targeted to extend the health span [19].
The pathophysiology of PF&S recapitulates all the hallmarks of aging [19–21], which makes it a
prototypical geroscience condition [22]. In this scenario, multivariate analyses of biomediators,
pertaining to different domains, may enable the identification of biomarkers for PF&S that capture its
pathophysiological complexity (Figure 1) [7–10,23]. The identified pathways may, eventually, be used
for drug development.
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Figure 1. Schematic representation of the main pathophysiological pathways contributing to physical
frailty and sarcopenia (PF&S) (i.e., inflammation, gut dysbiosis, declines in physical function,
and dysmetabolism), and related biomarkers. Abbreviations: DAMPs, damage-associated molecular
patterns; ROS, reactive oxygen species.
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Here, we will provide an overview of imaging, functional, and biological markers currently
available for PF&S. We will also illustrate the prospect of exploiting specific biological processes to
identify new biomarkers for the condition and to develop personalized interventions.
2. Imaging and Functional Markers
When Irwin Rosenberg prompted health professionals to pay serious attention to sarcopenia [24],
he referred exclusively to age-related muscle atrophy, while changes in physical function and mobility
were seen as possible secondary outcomes. Indeed, sarcopenia and muscle atrophy were synonyms
until the 2000s [25–27], after which findings from observational studies indicated that losses in physical
function occurred earlier, progressed more rapidly, and were better predictors of negative health-related
events than a decline in muscle mass [13,28]. Indeed, the recognition of declining physical performance
as a core feature of muscle aging has prompted the appraisal of sarcopenia as a composite condition
that encompasses quantitative (mass) and qualitative (strength/function) muscular domains [29,30].
Body imaging techniques (e.g., dual energy x-ray absorptiometry (DXA), computed tomography
(CT), and magnetic resonance imaging (MRI)) are popular tools for the quantification of muscle or lean
body mass [31]. However, all of them show notable pitfalls. Indeed, the results of DXA are heavily
influenced by body thickness, hydration status, and extracellular fluid accumulation. Furthermore,
DXA is unable to measure intramuscular adipose tissue [31]. On the other hand, the large-scale
implementation of CT and MRI is hampered by high costs, technological complexity, and space
requirements [31]. CT also exposes the test person to non-negligible doses of ionizing radiation.
The creatine (methyl-d3) dilution (D3-creatine) method is a recently developed approach that
allows the accurate quantification of whole-body muscle mass [32]. The method relies on the irreversible
conversion of creatine to creatinine, and its excretion in urine. The enrichment of urine D3-creatinine
allows estimating the total body creatine pool size as a proxy for the whole-body skeletal muscle mass.
This method involves the oral administration of stable isotope-labeled creatine (D3-creatine), followed
by the collection of a single fasted urine sample 48–96 h later. The sample is assayed for creatine and
creatinine (deuterated and unlabeled) via liquid chromatography mass spectrometry (LC-MS) [33–35].
By means of an algorithm, this method allows us to calculate the total body creatine pool size and
the muscle mass from D3-creatinine enrichment in urine [33–35]. Estimates of the total body muscle
mass, obtained by this method, show remarkable concordance with the whole-body MRI scans [33–35].
Differently from the DXA, the muscle mass quantified by the D3-creatine dilution method is strongly
correlated with physical performance, and predicts incidents of falls and functional limitations [36–39].
Physical function starts declining around the third decade of life, with a steeper decrease beyond
the age of 50, which suggests that the initial deflection of physical performance might be an early
predictor of sarcopenia [11,13–15]. However, physical performance refers to a wide construct involving
several components, including (but not limited to) muscle strength, power, and mobility. Therefore,
several physical abilities are legitimate functional biomarkers of sarcopenia. The identification of
specific components of physical function that, more so than others, predict sarcopenia is particularly
challenging, especially because knowledge of this condition has grown considerably in the last two
decades, as reflected by changes in its conceptual framework and operational definitions [30,40,41].
Muscle strength refers to the amount of force generated by a dynamic muscle contraction [42,43].
Isometric handgrip strength (IHG) and the five-time sit-to-stand test (5×STS) are two simple, inexpensive
and quick tests used to assess upper and lower limb muscle strength, respectively, in different settings,
including the community, hospitals, and nursing homes [4,29,30]. Cross-sectional [44–48] and
prospective studies [44,47,49–52] have reported that low IHG is significantly associated with poor
physical performance, mobility impairment, and disability. Notable findings by Rantanen et al. [52]
reported that men with low IHG during midlife were at higher risk of developing physical dysfunction
25 years later [52]. Although several studies support the hypothesis that IHG might predict physical
dysfunction (and, likely, also sarcopenia), there is also evidence indicating that IHG is not associated
with lower extremity disability [53]. Therefore, the combination of upper and lower limb muscle
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strength testing might be necessary for adequately framing sarcopenia. The 5×STS is associated with
many physical performance tests [54], progressive disability [53], and has been reported as a predictor
of sarcopenia in older Brazilian women [55]. However, larger studies, also including older men,
are needed to confirm and expand these initial findings.
Muscle power—the capacity to generate force in a short time interval—declines earlier in life and
at a faster rate, while presenting a higher degree of association with some mobility tasks than muscle
strength [13,56,57]. For instance, results from the InCHIANTI (Invecchiare in Chianti) study indicated
that women aged between 50 and 60 years had a 20–30% reduction of lower limb muscle strength,
while muscle power was reduced by ~50% [13]. Lower limb muscle power was also indicated as a
better discriminator of poor mobility than upper and lower limb muscle strength [13,57].
In an attempt to empower the discriminatory capacity of physical function as a marker of PF&S,
researchers have proposed combinations of physical tests that support the assessment of different
physical abilities. The short physical performance battery (SPPB) provides a single score based
on a person’s performance in balance tests, gait speed, and 5×STS [58]. In the seminal study by
Guralnik et al. [58], the authors observed that people with low SPPB scores were almost five times
more likely to develop disability in a short time interval. These findings were confirmed by a recent
systematic review and meta-analysis [59] that indicated that lower SPPB was associated with worsening
activities of daily living (ADL) and instrumental ADL.
Poor physical function is associated with chronic low-grade inflammation and antioxidant
markers in older adults [60–64], thus suggesting that physical dysfunction is likely mediated by cellular
mechanisms that, in combination with functional assessment, may be more informative than physical
function alone.
3. Inflammation-Related Biomarkers
Dysregulation of the cytokine network is a major driver of aging and related conditions [65–68].
However, the inclusion of inflammatory markers in clinical practice, as a tool for identifying specific
conditions, is far from being reached [19]. A core inflammatory profile with gender-specific signatures
has been identified in the context of PF&S as composed by higher levels of C-reactive protein and
lower concentrations of myeloperoxidase (MPO), interleukin (IL) 8, monocyte chemoattractant protein
1, and platelet-derived growth factor-BB (PDGF-BB). This set of mediators includes markers related to
immunosenescence [69,70], micronutrient intake imbalance [71,72], and impaired muscle regeneration,
in response to specific stimuli, such as oxidative stress [73–77]. Senescent cells face morphological
and functional reshaping, manifested by a senescence-associated secretory phenotype (SASP) [78].
The SASP fingerprint is composed of ILs, chemokines, growth factors, proteases, and extracellular matrix
components [78]. The release of these SASP factors induces perturbations in the local microenvironment
through autocrine and paracrine signals, in order to prevent proliferation of damaged cells, as well as
enabling the recruitment of immune cells and promoting tissue repair [79,80]. Age-related decline in
cell quality control systems may induce insufficient clearance of senescent cells and support systemic
inflammation, via the overproduction of SASP-related pro-inflammatory cytokines (e.g., IL1β, IL6,
and IL8) [81].
A pro-disability effect has long been attributed to the chronic low-grade inflammation observed
during aging, referred to as inflamm-aging [68,70,82]. Indeed, higher levels of pro-inflammatory
cytokines have been associated with muscle wasting and reduced physical performance [70,83].
This inflammatory response, void of infectious agents and named “sterile inflammation”, is part
of the innate immune response triggered by misplaced cellular components [84,85], which are
rooted into the “danger theory” of inflammation [86]. According to this theory, the accumulation of
damage-associated molecular patterns (DAMPs), and their release from injured cells into the circulation,
triggers inflammation via caspase-1 activation and the release of proinflammatory cytokines [87].
Among DAMP molecules, those of mitochondrial origin, in light of their bacterial ancestry, are thought
to contribute substantially to inflamm-aging by interacting with Toll-like receptors, NLR family
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pyrin domain containing 3 inflammasome activation, and cytosolic DNA sensing by the guanosine
monophosphate–adenosine monophosphate (GMP–AMP) synthase–stimulator of interferon gene
systems [88–90].
The mitochondrial involvement in the crosstalk between chronic inflammation and muscle wasting
is not surprising given the central role of this organelle in skeletal myocyte viability. Mitochondria are
highly interconnected organelles and form a dynamic network that operates via intra-mitochondrial
contacts (as well as with the endoplasmic reticulum, lysosomes, and the actin cytoskeleton) to guarantee
organelle homeostasis [91,92]. Recently, mitochondrial tubular protrusions, named mitochondrial
nanotunnels, have also been identified as additional structures for mitochondrial interconnections,
especially in mitochondria immobilized within post-mitotic tissues (e.g., skeletal muscle and cardiac
tissue) [92]. These resident organelles are structurally limited in their fusion, and thus may communicate
over long distances via nanotunnels [92]. Finally, Golgi-derived vesicles have been identified to
participate in mitochondrial dynamics and are newly described contact sites involved in mitochondrial
homeostasis [93]. However, the networking ability of mitochondria may be a double-edged sword.
Indeed, it is unclear where the boundary lies between the protective role of the inflammation-derived
circulating DAMPs and the detrimental effect of over-reactive inflammation. Severe mitochondrial
damage and abnormal autophagosome formation were found in the skeletal muscle of IL10-null mice
(IL10tm/tm), a rodent model of chronic inflammation and frailty [94]. Among mitochondrial DAMPs,
circulating mitochondrial DNA (mtDNA) released from damaged organelles is a prominent candidate,
linking inflammation with muscle decay [85]. Recent findings by our group support the hypothesis
of mitochondrial impairment among the underlying pathogenetic mechanisms of sarcopenia [18].
In particular, as a result of failing quality control systems [91,95–97], the release of oxidized cell-free
mtDNA and other mitochondrial components within MDVs have been associated with systemic
inflammation in older adults with PF&S [7].
The characterization of the composition of exosomes/EVs released by senescent cells (eSASP)
has revealed a specific EV SASP signature [98] from which it has been possible to track down their
originating cells [99,100]. Therefore, EVs represent a unique tool for capturing the regulatory network
of complex conditions and for the identification of cell- and stressor-specific biomarkers. The dissection
of these pathways may provide relevant insights into the role played by inflammation in the disabling
cascade of PF&S, allowing for the design of personalized treatment strategies.
4. Metabolic Markers
The analysis of the wide collection of endogenous metabolites in biological matrices, referred to
as metabolomics, allows for the exploration of genotype–phenotype interactions under the impact of
the environment. As such, metabolomics supports the analysis of the dynamic changes of organismal
function and provides more informative data than gene or protein expression assays [101–104]. In the
context of PF&S, the study of the dynamic metabolic responses to stressors and the characterization of
the biochemical pathways involved are particularly relevant, as this condition is tightly associated
with metabolic disorders [105,106].
Dietary protein and amino acids are building blocks for muscle protein synthesis and relevant
factors for muscle plasticity and trophism [107]. Furthermore, these metabolites are at the crossroads
of multiple biological processes, such as inflammation, insulin sensitivity, and redox homeostasis—all
of which are candidates for age-related muscle atrophy and dysfunction [108,109]. Therefore,
disarrangements in protein–amino acid metabolism may contribute substantially to the pathophysiology
of sarcopenia [110,111].
Specific patterns of circulating amino acids have been associated with muscle mass [112] and
quality [113] in functionally limited older adults. In particular, lower plasma concentrations of the
branched-chain amino acids leucine and isoleucine have been found in sarcopenic, older Norwegian
community dwellers [114]. Conversely, higher concentrations of proline characterized older Japanese
people with sarcopenia [115]. Finally, it was found that frail older Japanese people had low levels of
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essential amino acids, compared with their non-frail peers [116]. On coupling the circulating-amino-acid
profiling with the multivariate statistical modeling, the discriminatory power of the analytical approach
enabled the exploration of the interrelationship between the protein–amino acid dyshomeostasis and
PF&S [117]. Indeed, as observed in the BIOmarkers associated with Sarcopenia and PHysical frailty in
EldeRly pErsons (BIOSPHERE) study, metabolomics coupled with a partial least squares–discriminant
analysis (PLS-DA) allowed the distinct signatures of circulating amino acids and derivatives in older
adults, with and without PF&S, to be identified [9,23]. In particular, participants with PF&S were
characterized by higher serum levels of asparagine, aspartic acid, citrulline, ethanolamine, glutamic
acid, sarcosine, and taurine, while higher concentrations of alpha amino butyric acid and methionine
were found in non-PF&S controls [23]. Notably, the metabolic profile of people with PF&S was
associated with a decrease in total energy, as well as the quality and quantity of dietary protein
intake [23]. In particular, a link between a poor-quality protein diet or (selective) malabsorption and an
impaired mitochondrial quality control mechanism was reported [23]. These findings are in keeping
with results from the cross-sectional Maastricht Sarcopenia study (MaSS) in which selected nutritional
biomarkers (e.g., essential amino acids, branched-chain amino acids, and eicosapentaenoic acid) were
decreased in older, sarcopenic adults [118].
In a recent study by our group, multi-marker datasets (which include mediators pertaining to
inflammation, metabolism, and mitochondrial dysfunction) were analyzed through an innovative
strategy based on Sequential and Orthogonalized Covariance Selection (SO-CovSel) [22]. This approach
allowed us to scale down the number of discriminant biomarkers for PF&S to only seven
biomolecules (α-aminobutyric acid, asparagine, aspartic acid, citrulline, heat shock protein 72, MPO,
and PDGF-BB) [22], which may speed up the implementation of cost-effective biomarkers in the clinical
arena. These findings, albeit promising, need to be confirmed in larger-scale, longitudinal studies to
integrate composite biochemical measurements into the routine assessment of PF&S.
5. Gut Microbiota
Past the age of 70, gut microbiota face substantial compositional and functional modifications [119,120]
of which higher inter-individual variability, reduced biodiversity, and colonization by pathobionts are the
main features (Figure 1) [119,120]. These changes, collectively referred to as gut dysbiosis, impact host
physiology and expose older adults to a higher risk of infections [119,120]. Furthermore, gut dysbiosis is
implicated in acute and chronic conditions, beyond the gastrointestinal system [120,121]. The cause–effect
inferences between the gut dysbiosis and human diseases cannot yet be established [121]. However, growing
evidence supports the existence of a relationship between changes in gut flora, chronic inflammation,
and anabolic resistance in muscle wasting [122,123]. As such, gut dysbiosis has been proposed as a factor in
the development of PF&S [124,125]. This view is supported by the observation that supplementation
with specific Lactobacillus strains attenuates muscle wasting in a mouse model of acute leukemia [126],
possibly via increased amino acid bioavailability. Indeed, the activity of host- and bacterium-derived
proteases and peptidases along the gastrointestinal tract supports the hydrolysis of dietary proteins
into peptides and amino acids [127,128]. These bioproducts, in turn, influence microbial growth and
survival [129], and regulate energy and the protein homeostasis of the host [130,131]. Amino acids are
also precursors of short chain fatty acids (SCFAs), particularly acetate, propionate and butyrate [132],
of which acetate is mainly metabolized by muscle cells to produce energy [133].
The age-related decline in the barrier function of the gut mucosa is believed to play a major role
in gut dysbiosis [134]. The establishment of a “leaky gut” during aging may favor the entry of gut
microbes and/or related products into the circulation, where they trigger inflammation and contribute
to immune system dysregulation [135,136]. In physiologic conditions, the gut flora balances pro- and
anti-inflammatory responses [137]. Age-associated dysbiosis weakens the action of gut flora against
adverse microbial colonization or metabolite removal [138]. In conjunction with this, the secretion
of mucins by intestinal cells and the consequent reduction of SCFAs render the intestinal mucosa
more permissive of pathogens entering [138,139]. Apart from being an energy source for colonic
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epithelial cells, SCFAs modulate the release of anti-inflammatory molecules, which are involved in
host metabolism and immunity [140]. In particular, butyrate regulates the differentiation of CD4+ T
cells into regulatory T cells, the induction of transforming growth factors β secretion by epithelial
cells, and the production of IL10 and retinoic acid by dendritic cells and macrophages [140]. Therefore,
local intestinal inflammation and its propagation, via the leakage of microbes and bacterium-derived
inflammatory compounds into the blood, are blunted [140]. In further support of a link between gut
dysbiosis and systemic inflammation are findings from a study where young mice were fed a high-fat
diet—a known inducer of intestinal permeability [141]. In these rodents, systemic inflammation and
leakage of lipopolysaccharide from the intestine into the circulation were described [141].
Chronic inflammation has been indicated as a trait d’union between gut dysbiosis and muscle
structural and functional decline [124,125]. The determinants of this crosstalk are unclear, although
studies in preclinical models have offered interesting clues. Germ-free mice are preserved from
dietary-induced obesity via increased fatty acid metabolism [142]. This phenomenon occurs via
activation of the 5′ adenosine monophosphate–activated protein kinase pathway, a gatekeeper of cellular
energy status that activates the carnitine:palmitoyl transferase-1 in the muscle. As a result, mitochondria
may be fueled by long chain fatty acylCoA and higher levels of the fasting-induced adipocyte factor,
linked to the peroxisome proliferator-activated receptor, and gamma coactivator 1-alpha, the master
regulator of mitochondrial biogenesis and oxidative metabolism [142]. The orchestration of these
activities may assist in counteracting muscle atrophy.
Age-associated changes in the gut flora composition have been related to the progression of
diseases and frailty in older adults. Van Tongeren et al. [143] were the first to report an association
between the composition of gut microbiota and frailty. In particular, a reduction in the proportion of
Lactobacilli, Bacterioides/Prevotella, and Faecalibacterium prausnitzii, and an increase in the proportion
of Ruminococcus, Atopobium, and Enterobacteriacae were found in individuals showing high frailty
scores [143]. The reduced abundance of butyrate-producing bacteria (e.g., Faecalibacterium prausnitzii)
in frail older adults suggests a positive role for butyrate, namely in reinforcing the tight junctions of
intestinal cells and preventing microbial spread into the circulation [144]. The reduced inflammation
may, in turn, sustain muscle health [145]. Subsequent results from the ELDERMET study provided
further confirmation of this hypothesis and linked butyrate-generating bacteria with functional capacity
in older community-dwelling adults [146].
Finally, the application of a multi-marker analytical approach allowed identifying patterns
of circulating mediators, which are composed of higher serum concentrations of aspartic acid,
lower circulating levels of concentrations of threonine, and the macrophage inflammatory protein 1α
(associated with increased abundance of Oscillospira and Ruminococcus microbial taxa, and decreased
abundance of Barnesiellaceae and Christensenellaceae in older people with PF&S) [8]. The relationship
between the abundance of specific intestinal bacteria, metabolic markers, and serum levels of specific
inflammatory biomolecules suggests the existence of an additional pathway through which changes in
gut microbiota may impinge on PF&S pathophysiology [8].
6. Conclusions
To date, the identification of PF&S relies upon clinical, functional, and imaging parameters.
However, biological mediators pertaining to different domains (e.g., inflammation, amino acid
metabolism, and gut microbiota) have been identified as candidate biomarkers for the condition
(Table 1).
Although a fairly large number of metabolic, microbial, and inflammatory biomolecules have been
investigated for their association with PF&S, it cannot be excluded that other relevant markers might
be obtained through the analysis of a larger set of biomediators. In light of this limitation (and the
lack of a “gold standard” biomarker that can reliably predict functional impairment in older adults),
the incorporation of these biological markers into clinical practice is yet to be achieved. The adoption
of multi-marker approaches combined with multivariate modeling has shown great potential for
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addressing the complexity of PF&S pathophysiology and unveiling novel targets for interventions.
Well-designed longitudinal studies are warranted to accomplish these ambitious tasks.
Table 1. Biological markers associated with PF&S operationalized, according to the Sarcopenia and
Physical fRailty IN older people: multi-componenT Treatment strategies (SPRINTT) project’s definition.
Biological Domain Biomarkers
Inflammation CRP, HSP72, IL1β, IL6, IL8, MCP1, MIP1α, MPO, PDGF-BB
Amino acid metabolism Asparagine, aspartic acid, citrulline, ethanolamine, glutamic acid,sarcosine, taurine, threonine
Gut microbiota Barnesiellaceae, Christensenellaceae, Oscillospira, Ruminococcus
Abbreviations: CRP, C-reactive protein; HSP72, heat shock protein 72; IL, interleukin; MCP1, monocyte
chemoattractant protein 1; MIP1α, macrophage inflammatory protein 1α; MPO, myeloperoxidase; PDGF-BB,
platelet-derived growth factor-BB.
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Abbreviations
5 × STS Five-time sit-to-stand
ADL Activities of daily living
BIOSPHERE BIOmarkers associated with Sarcopenia and PHysical frailty in EldeRly pErsons
CRP C-reactive protein
CT Computed tomography
DAMPs Damage-associated molecular patterns
DXA Dual energy x-ray absorptiometry
HSP72 HSP72, heat shock protein 72
IHG Isometric handgrip strength
IL Interleukin
MaSS Maastricht Sarcopenia study
MCP1 Monocyte chemoattractant protein 1
MDVs Mitochondrial-derived vesicles
MIP1α Macrophage inflammatory protein 1α
MPO Myeloperoxidase
MRI Magnetic resonance imaging
PDGF-BB Platelet-derived growth factor-BB
PF&S Physical frailty and sarcopenia
PLS-DA Partial Least Squares–Discriminant Analysis
SASP Senescence-associated secretory phenotype
SCFAs Short chain fatty acids
SPRINTT Sarcopenia and Physical fRailty IN older people: multi-componenT Treatment strategies
sEVs Small extracellular vesicle
SO-CovSel Sequential and Orthogonalized Covariance Selection
SPPB Short physical performance battery
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